yahoo.comAUG 222 min read$CVS

CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.

CVS Health (NYSE: CVS) shares have risen 18% YTD, outperforming the S&P 500. Analysts expect a 22% upside to $114.59. CVS beat earnings estimates in all three 2026 quarters, with strong healthcare benefits segment performance. 16 of 17 analysts rate it a buy, with UBS targeting $126. Growth driven by insurance operations and an aging population.

Original reporting

yahoo.com

Published Aug 22, 2026, 5:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 22, 2026, 5:33 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%. — source image — Source · yahoo.com

Decision brief

The 30-second read

$CVSBullishMed

Why it matters

Earnings beat and guidance raise reinforce bullish outlook, but PBM challenges remain.

Market read

Positive earnings surprise and higher guidance could drive short‑term buying pressure in CVS and related health‑care stocks.

What to watch

Potential headwinds from regulatory scrutiny of PBM practices and competitive pressure.

Relevance 7/10Novelty 6/10Timing: post‑earnings release today

Background

CVS Health is a large integrated pharmacy and health‑care benefits provider.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CVSBullishMedium confidence

Context

CVS reported two consecutive quarters beating analyst estimates and raised both top‑line and bottom‑line guidance.

Expected impact

Potential short‑term price rally as investors price in higher earnings outlook.

Evidence & confidence

Guidance raise after strong earnings is a fresh catalyst that can move the stock.

Market effects

Sector

Strong performance may lift broader healthcare and pharmacy retail sector.

Regional

U.S. market may see modest gain in health‑care indices.

Global

Limited to U.S. investors; no direct global impact.

Counterpoint

What could challenge this read

Some analysts note operational missteps at CVS Caremark PBM that could temper upside.

Key entities

company
CVS Health
U.S. pharmacy and health‑care benefits operator.
business unit
Aetna
Health‑insurance segment of CVS Health.

Read at source ← All news

AUG 20

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min

AUG 18

$CNCMedAI 8/10

CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

stocktwits.com2 min

AUG 15

$CVSMed

CVS Health Stock's Next Leg Sits In Aetna's Unfinished Margin Repair

CVS Health (CVS) shares were up 0.2% over three months as management raised full-year 2026 guidance for Health Care Benefits adjusted operating income by more than $1B, citing Aetna margin recovery. Enterprise adjusted EPS guidance is $7.90 to $8.10 and operating cash flow at least $11.5B. CVS flags 2027 headwinds at Caremark from 340B and membership declines.

yahoo.com6 min

AUG 14

$CVSMedAI 8/10

Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance?

CVS Health raised 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and lifted consolidated revenue to at least $414B, plus adjusted operating income to $16.58-$16.92B and operating cash flow to at least $11.5B, after Q2 adjusted EPS rose 42.5% to $2.58 and revenues rose 7.3% to $106.1B. Aetna margin recovery drove results, though medical-cost and pharmacy-services risks remain.

zacks.com6 min

AUG 12

$CVSHighAI 9/10

CVS Health (CVS) Q2 2026 Earnings Call Transcript

CVS Health reported Q2 2026 results on its earnings call. Total revenue was $106.1B (+7.3%), adjusted EPS $2.58 (+42.5%), and adjusted operating income $5.2B (+35.4%). It raised 2026 guidance to adjusted EPS $7.90 to $8.10 and revenue at least $414B, with cash flow from operations at least $11.5B. 2027 EPS floor was $8.44.

fool.com6 min

AUG 11